Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients

Metabolism: Clinical and Experimental

Volumn 45, Issue SUPPL.1, 1996, Pages 67-71

  Lancranjan, I ^a   Bruns, C ^b   Grass, P ^b   Jaquet, P ^b   Jervell, J ^b   Kendall Taylor, P ^b   Lamberts, S W J ^b   Marbach, P ^b   Orskov H ^b   Pagani, G ^b   Sheppard, M ^b   Simionescu, L ^b  

^a Sandoz Pharma Ltd   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; MICROSPHERE;

ACROMEGALY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GROWTH HORMONE RELEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ADENOMA; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HYPOPHYSIS TUMOR; MICROCAPSULE; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACROMEGALY; ADENOMA; CAPSULES; DOUBLE-BLIND METHOD; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICROSPHERES; OCTREOTIDE; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES;

EID: 10444279988     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90087-6     Document Type: Article

References (3)

1. Lancranjan I, Bruns C, Grass P, et al: Sandostatin® LAR®: Pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients. Metab Clin Exp 44:18-26,1995 (suppl 1)
2. Kaal A, Frystyk J, Skjserbafk C, et al: Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. Metab Clin Exp 44:6-14, 1995 (suppl 1)
3. Montini M, Pedroncelli A, Ene-Iordache B, et al: Sandostatin® LAR® in acromegaly: Clinical and therapeutic efficacy. Program and Abstracts, 77th Annual Meeting, The Endocrine Society, June 1995, p 361 (abstr P2-284)